Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

American Medical Systems Holdings, Inc. (NASDAQ: AMMD) reported Preliminary sales for the year 2008 were at $501.6 million, an 8.1 percent increase over sales of $463.9 million for the year 2007.

In anticipation of presenting at the JP Morgan Healthcare Conference on January 13, 2009, American Medical Systems Holdings, Inc. (NASDAQ: AMMD) reported today preliminary sales of $134.0 million for the fourth quarter of 2008, a 3.0 percent increase over sales of $130.0 million in the comparable quarter of 2007. The fourth quarter growth over last year was negatively impacted by foreign currency fluctuations. The strengthening of the U.S. dollar negatively affected revenue for the quarter by $3.8 million, compared to the fourth quarter of 2007. Adjusting for the negative impact of the stronger U.S. dollar results in fourth quarter growth of 5.9 percent over the same period last year. Preliminary sales for the year 2008 were reported at $501.6 million, an 8.1 percent increase over sales of $463.9 million for the year 2007.

The men's health business grew 0.8 percent to $88.9 million in the fourth quarter. Fourth quarter men's health sales were hampered by a slowing of the growth rate for erectile restoration, and a 9.4 percent decline in laser therapy. While the economy has impacted growth in erectile restoration, we saw strong performance in male continence which continues to experience market expansion driven by the AdVance®sling system used to address mild male incontinence.

The fourth quarter women's health business grew 7.8 percent to $45.1 million. The female continence product line continued strong double digit growth led by theMiniArc® Single- Incision Sling system. The prolapse repair product line also achieved double digit growth in the fourth quarter, driven by the recent launch of theElevate® posterior product offering.

"We are excited to achieve the half billion dollar sales milestone," noted Tony Bihl, Chief Executive Officer. "However, most notable in the fourth quarter were the rapid acceptance of the Elevate® posterior product and the FDA approval of the Elevate® anterior product late in the fourth quarter. We will perform a limited release ofElevate® anterior in the first half of 2009 and look forward to full commercial launch by the third quarter of 2009."

Mr. Bihl further commented, "Our fourth quarter revenue performance exceeded our previously disclosed guidance issued on November 4, 2008 of $126 million to $132 million. Despite exceeding the revenue guidance we are reiterating our previously issued fourth quarter earnings per share guidance of $0.21 to $0.25, excluding the impact of any potential unusual non-recurring charges. We will be providing final fourth quarter and full year 2008 EPS results, along with 2009 guidance on our fourth quarter earnings call scheduled for February 17, 2009."

The Company will participate in the 27^th Annual JP Morgan Healthcare Conference on Tuesday, January 13, 2009 in San Francisco. Tony Bihl, Chief Executive Officer, and Mark Heggestad, Chief Financial Officer, will present to attendees of the conference at 7:30 a.m. pacific time (10:30 a.m. eastern time).

Earnings Call Information

American Medical Systems will host a conference call on Tuesday, February 17, 2009 at 5:00 p.m. eastern time to discuss its fourth quarter and full year results for 2008. The Company will also provide guidance for 2009 on this call. Those without internet access may join the call from within the U.S. by dialing 888-263-1724; outside the U.S., dial 706-679-3821.

Forward-Looking Statements

This press release contains forward-looking statements relating to the market opportunities, future products, sales and financial results of American Medical Systems. These statements and other statements contained in this press release that are not purely historical fact are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on management's beliefs, certain assumptions and current expectations. These forward-looking statements are subject to risks and uncertainties such as successfully competing against competitors; physician acceptance, endorsement, and use of AMS products; potential product recalls or technological obsolescence; successfully managing increased debt leverage and related credit facility financial covenants; the impact on operations of the disruption in global financial markets, factors impacting the stock market and share price and its impact on the dilution of convertible securities; changes in the accounting method for convertible debt securities; potential obligations to make significant contingent payments under prior acquisitions; ability of the Company's manufacturing facilities to meet customer demand; reliance on single or sole-sourced suppliers; loss or impairment of a principal manufacturing facility; clinical and regulatory matters; timing and success of new product introductions; patient acceptance of the Company's products and therapies; changes in and adoption of reimbursement rates; adequate protection of the Company's intellectual property rights; product liability claims; currency and other economic risks inherent in selling our products internationally and other risks and uncertainties described in the Company's Annual Report on Form 10-K for the year ended December 29, 2007, and its other SEC filings. Actual results may differ materially from anticipated results. The forward-looking statements contained in this press release are made as of the date hereof, and AMS undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Source: American Medical Systems